Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Hongying Zhang, MD PhD, Andrea Local, PhD, Khalid Benbatoul, Peter Folger, Susan Sheng, PhD, Luis Esquivies, PhD, Jeff Lightfoot, PhD, Avanish Vellanki, William G. Rice, PhD

Blood (2016) 128 (22): 1716.

https://doi.org/10.1182/blood.V128.22.1716.1716

Published: 2016

Journal Articles

Discovery of Selective Dual Inhibitors of Bromodomain Protein BRD4 and JAK2 for Treatment of Hematologic Malignancies

Ram S. Upadhayaya, PhD, Raghava Reddy Kethiri, PhD, Avanish Vellanki, Jeff Lightfoot, PhD, Andrea Local, PhD, William G. Rice, PhD

Blood (2016) 128 (22): 5212.

https://doi.org/10.1182/blood.V128.22.5212.5212

Published: 2016

Journal Articles

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Stephen E. Kurtz, PhD, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, William Rice, PhD, Stephen B Howell, MD, Avanish Vellanki, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 1358.

https://doi.org/10.1182/blood.V126.23.1358.1358

Published: 2015

Journal Articles

Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies

William G. Rice, PhD, Jeff Lightfoot, PhD, Hongying Zhang, MD PhD, Tiffany Cheng, MSc, Avanish Vellanki, Robert Peralta, MSc, DVM, Stephen B Howell, MD, Andrea Local, Fannie Chau, Luis Esquivies

Blood (2015) 126 (23): 4934.

https://doi.org/10.1182/blood.V126.23.4934.4934

Published: 2015

Journal Articles

APTO-253 Induces KLF4 to Promote Potent in Vitro Pro-Apoptotic Activity in Hematologic Cancer Cell Lines and Antitumor Efficacy As a Single Agent and in Combination with Azacitidine in Animal Models of Acute Myelogenous Leukemia (AML)

William G Rice, PhD, Avanish Vellanki, MBS, MBA, Yoon Lee, PhD, Jeff Lightfoot, PhD, Robert Peralta, MSc, DVM, Mona Jamerlan, MSc, Hongnan Jin, Ronnie Lum, PhD, Tiffany Cheng, MSc

Blood (2014) 124 (21): 4813.

https://doi.org/10.1182/blood.V124.21.4813.4813

Published: 2014

NARROW

Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Discovery of Selective Dual Inhibitors of Bromodomain Protein BRD4 and JAK2 for Treatment of Hematologic Malignancies

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies

APTO-253 Induces KLF4 to Promote Potent in Vitro Pro-Apoptotic Activity in Hematologic Cancer Cell Lines and Antitumor Efficacy As a Single Agent and in Combination with Azacitidine in Animal Models of Acute Myelogenous Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Discovery of Selective Dual Inhibitors of Bromodomain Protein BRD4 and JAK2 for Treatment of Hematologic Malignancies

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies

APTO-253 Induces KLF4 to Promote Potent in Vitro Pro-Apoptotic Activity in Hematologic Cancer Cell Lines and Antitumor Efficacy As a Single Agent and in Combination with Azacitidine in Animal Models of Acute Myelogenous Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only